Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

344 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial.
Bouchart C, Navez J, Borbath I, Geboes K, Vandamme T, Closset J, Moretti L, Demetter P, Paesmans M, Van Laethem JL. Bouchart C, et al. Among authors: paesmans m. BMC Cancer. 2023 Sep 21;23(1):891. doi: 10.1186/s12885-023-11327-x. BMC Cancer. 2023. PMID: 37735634 Free PMC article.
HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, Dolci S, Leroy JY, Paesmans M, Isola J, Piccart MJ. Di Leo A, et al. Among authors: paesmans m. Clin Cancer Res. 2002 May;8(5):1107-16. Clin Cancer Res. 2002. PMID: 12006526 Clinical Trial.
Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer.
Personeni N, Hendlisz A, Gallez J, Galdon MG, Larsimont D, Van Laethem JL, Nagy N, Barette M, Paesmans M, Cardoso F, Bleiberg H. Personeni N, et al. Among authors: paesmans m. Semin Oncol. 2005 Dec;32(6 Suppl 9):S59-62. doi: 10.1053/j.seminoncol.2005.04.029. Semin Oncol. 2005. PMID: 16399434
Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy.
Hendlisz A, Van den Eynde M, Peeters M, Maleux G, Lambert B, Vannoote J, De Keukeleire K, Verslype C, Defreyne L, Van Cutsem E, Delatte P, Delaunoit T, Personeni N, Paesmans M, Van Laethem JL, Flamen P. Hendlisz A, et al. Among authors: paesmans m. J Clin Oncol. 2010 Aug 10;28(23):3687-94. doi: 10.1200/JCO.2010.28.5643. Epub 2010 Jun 21. J Clin Oncol. 2010. PMID: 20567019 Clinical Trial.
Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study.
Hendlisz A, Golfinopoulos V, Deleporte A, Paesmans M, Mansy HE, Garcia C, Peeters M, Annemans L, Vandeputte C, Maetens M, Borbath I, Dresse D, Houbiers G, Fried M, Awada A, Piccart M, Laethem JL, Flamen P. Hendlisz A, et al. Among authors: paesmans m. BMC Cancer. 2013 Apr 12;13:190. doi: 10.1186/1471-2407-13-190. BMC Cancer. 2013. PMID: 23587148 Free PMC article.
Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient's outcome in advanced colorectal cancer: the CORIOLAN study.
Deleporte A, Paesmans M, Garcia C, Vandeputte C, Lemort M, Engelholm JL, Hoerner F, Aftimos P, Awada A, Charette N, Machiels G, Piccart M, Flamen P, Hendlisz A. Deleporte A, et al. Among authors: paesmans m. BMC Cancer. 2014 May 30;14:385. doi: 10.1186/1471-2407-14-385. BMC Cancer. 2014. PMID: 24885112 Free PMC article. Clinical Trial.
Systematic qualitative review of randomised trials conducted in nonsmall cell lung cancer with a noninferiority or equivalence design.
Paesmans M, Grigoriu B, Ocak S, Roelandts M, Lafitte JJ, Holbrechts S, Berghmans T, Meert AP, Moretti L, Danyi S, Pasleau F, Ameye L, Van Meerhaeghe A, Sculier JP. Paesmans M, et al. Eur Respir J. 2015 Feb;45(2):511-24. doi: 10.1183/09031936.00092814. Epub 2014 Dec 23. Eur Respir J. 2015. PMID: 25537559 Free article. Review.
Erratum: preoperative chemosensitivity testing as predictor of treatment benefit in adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study.
Hendlisz A, Golfinopoulos V, Deleporte A, Paesmans M, El Mansy H, Garcia C, Peeters M, Annemans L, Vandeputte C, Maetens M, Van den Eynde M, Maréchal R, Borbath I, Dresse D, Houbiers G, Fried M, Awada A, Piccart M, Van Laethem JL, Flamen P. Hendlisz A, et al. Among authors: paesmans m. BMC Cancer. 2015 Mar 25;15:173. doi: 10.1186/s12885-015-1181-5. BMC Cancer. 2015. PMID: 25879441 Free PMC article. No abstract available.
The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer.
Hendlisz A, Deleporte A, Delaunoit T, Maréchal R, Peeters M, Holbrechts S, Van den Eynde M, Houbiers G, Filleul B, Van Laethem JL, Ceyssens S, Barbuto AM, Lhommel R, Demolin G, Garcia C, El Mansy H, Ameye L, Moreau M, Guiot T, Paesmans M, Piccart M, Flamen P. Hendlisz A, et al. Among authors: paesmans m. PLoS One. 2015 Sep 30;10(9):e0138341. doi: 10.1371/journal.pone.0138341. eCollection 2015. PLoS One. 2015. PMID: 26421426 Free PMC article. Clinical Trial.
344 results